Switching to riociguat for pulmonary hypertension
Part of Lungs & breathing clinical trials.
This study looks at how well a medicine called riociguat works for people with pulmonary arterial hypertension when they switch to it from another similar medicine (a PDE5 inhibitor) while already taking two other blood vessel-relaxing medicines. The goal is to see if the switch helps improve their condition over 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pulmonary arterial hypertension (Group 1).
- You have been taking a combination of three medicines for at least 12 weeks: an endothelin receptor antagonist, a prostacyclin pathway agent, and a PDE5 inhibitor.
- Your doctor is planning to switch you from the PDE5 inhibitor to riociguat as part of your regular care.
- You are not currently taking both a PDE5 inhibitor and riociguat at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This trial tests switching from sildenafil to a newer medicine called riociguat for people with CTEPH (a type of lung blood pressure problem) who still have symptoms after a balloon procedure. The goal is to see if the switch helps them feel better.
This trial compares what happens when people with chronic thromboembolic pulmonary hypertension (CTEPH) either stop or continue taking the medication riociguat after they have done well following a procedure called balloon pulmonary angioplasty. The goal is to learn whether it is safe and better to stop the medication or keep taking it.
This trial is for people with a type of long-term blood clot in the lungs (CTEPH) who have been taking riociguat for at least 12 weeks. It will see what happens when the medication is stopped, focusing on how the right side of the heart is doing.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.